Authors
Mark L Hudak, Rosemarie C Tan, Committee on Drugs, Committee on Fetus and Newborn, Daniel AC Frattarelli, Jeffrey L Galinkin, Thomas P Green, Kathleen A Neville, Ian M Paul, John N Van Den Anker, Lu-Ann Papile, Jill E Baley, Vinod K Bhutani, Waldemar A Carlo, James Cummings, Praveen Kumar, Richard A Polin, Kasper S Wang, Kristi L Watterberg
Publication date
2012/2/1
Journal
Pediatrics
Volume
129
Issue
2
Pages
e540-e560
Publisher
American Academy of Pediatrics
Description
Maternal use of certain drugs during pregnancy can result in transient neonatal signs consistent with withdrawal or acute toxicity or cause sustained signs consistent with a lasting drug effect. In addition, hospitalized infants who are treated with opioids or benzodiazepines to provide analgesia or sedation may be at risk for manifesting signs of withdrawal. This statement updates information about the clinical presentation of infants exposed to intrauterine drugs and the therapeutic options for treatment of withdrawal and is expanded to include evidence-based approaches to the management of the hospitalized infant who requires weaning from analgesics or sedatives.
Total citations
20122013201420152016201720182019202020212022202320241341599776109114115107109796827
Scholar articles
ML Hudak, RC Tan, Committee on Drugs… - Pediatrics, 2012